Acute graft-versus-host disease

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Scopus citations


Despite advances in HLA typing, acute GvHD remains a leading cause of morbidity and mortality among allogeneic transplant recipients. It is estimated that 30-50% of patients who receive stem cell products from HLA-identical siblings will develop grades 2-4 GvHD, while rates of GvHD in matched unrelated donor transplants are estimated to be between 50 and 70%. Acute GvHD has historically been defined as occurring prior to day +100 and chronic GvHD as occurring after day +100. However, recently there has been a move to define GvHD based on the clinical symptoms and pathologic findings rather than by an arbitrary timeline. The outcome of acute GvHD is dependent on the overall grade of GvHD and the patient's response to initial treatment.

Original languageEnglish (US)
Title of host publicationBlood and Marrow Transplant Handbook
Subtitle of host publicationComprehensive Guide for Patient Care
PublisherSpringer New York
Number of pages21
ISBN (Print)9781441975058
StatePublished - 2011

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Acute graft-versus-host disease'. Together they form a unique fingerprint.

Cite this